Medicofarma Biotech (MDB) Stock Overview
A biotechnology company, provides medicines, medicinal products, and biotechnology products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
MDB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Medicofarma Biotech SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.70 |
| 52 Week High | zł1.40 |
| 52 Week Low | zł0.23 |
| Beta | 3.9 |
| 1 Month Change | 119.44% |
| 3 Month Change | 149.11% |
| 1 Year Change | 33.59% |
| 3 Year Change | -36.36% |
| 5 Year Change | -50.70% |
| Change since IPO | -46.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDB | PL Life Sciences | PL Market | |
|---|---|---|---|
| 7D | -10.5% | 0.5% | 1.0% |
| 1Y | 33.6% | -37.3% | 25.5% |
Return vs Industry: MDB exceeded the Polish Life Sciences industry which returned -36.6% over the past year.
Return vs Market: MDB exceeded the Polish Market which returned 25.6% over the past year.
Price Volatility
| MDB volatility | |
|---|---|
| MDB Average Weekly Movement | 44.6% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in PL Market | 9.9% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: MDB's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: MDB's weekly volatility has increased from 25% to 45% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 15 | Cezary Kilczewski | medicofarmabiotech.pl |
Medicofarma Biotech SA, a biotechnology company, provides medicines, medicinal products, and biotechnology products. The company is involved in the research and development works in collaboration with pharmaceutical and cosmetic manufacturing plants, as well as research units. It also offers staff support and equipment during the early stages of development of generic pharmaceutical products and cosmetics; and covid-19 test kits, such as real time PCR genetic tests.
Medicofarma Biotech SA Fundamentals Summary
| MDB fundamental statistics | |
|---|---|
| Market cap | zł47.58m |
| Earnings (TTM) | -zł3.21m |
| Revenue (TTM) | zł279.31k |
Is MDB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDB income statement (TTM) | |
|---|---|
| Revenue | zł279.31k |
| Cost of Revenue | zł1.55m |
| Gross Profit | -zł1.27m |
| Other Expenses | zł1.94m |
| Earnings | -zł3.21m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.047 |
| Gross Margin | -454.29% |
| Net Profit Margin | -1,148.27% |
| Debt/Equity Ratio | 57.1% |
How did MDB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 16:32 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medicofarma Biotech SA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.